Core Viewpoint - The stock of Lijun Thermal Energy has shown fluctuations with a recent increase of 2.05%, while the company faces a decline in revenue and net profit for the first half of 2025 compared to the previous year [1][2]. Financial Performance - As of October 22, Lijun Thermal Energy's stock price is 50.67 CNY per share, with a market capitalization of 4.611 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 24.07%, but a decline of 6.99% over the last five trading days [1]. - For the first half of 2025, Lijun Thermal Energy reported a revenue of 404 million CNY, a decrease of 11.60% year-on-year, and a net profit of 52.55 million CNY, down 32.66% year-on-year [2]. Shareholder Information - As of October 10, the number of shareholders for Lijun Thermal Energy is 6,426, a decrease of 2.12% from the previous period [2]. - The average number of circulating shares per shareholder has increased by 2.16% to 3,540 shares [2]. Dividend and Institutional Holdings - Lijun Thermal Energy has distributed a total of 227 million CNY in dividends since its A-share listing [3]. - As of June 30, 2025, major institutional shareholders include Taikang Quality Life Mixed Fund, which increased its holdings by 150,000 shares, and Taikang Strategy Preferred Mixed Fund, which increased its holdings by 140,000 shares [3].

Core Viewpoint - The stock price of Jinhuijiu has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 3.98%, indicating mixed performance in the market [1][2]. Company Overview - Jinhuijiu Co., Ltd. is located in Huixian, Longnan City, Gansu Province, established on December 23, 2009, and listed on March 10, 2016. The company specializes in the production and sales of liquor [2]. - The main business revenue composition is as follows: 55.10% from products priced between 100-300 yuan, 21.62% from products priced above 300 yuan, and 20.82% from products priced below 100 yuan [2]. Financial Performance - For the first half of 2025, Jinhuijiu achieved an operating income of 1.759 billion yuan, a year-on-year increase of 0.31%, and a net profit attributable to shareholders of 298 million yuan, a year-on-year increase of 1.12% [2]. - Since its A-share listing, Jinhuijiu has distributed a total of 1.168 billion yuan in dividends, with 598 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders of Jinhuijiu is 44,500, a decrease of 7.68% from the previous period, with an average of 11,408 circulating shares per person, an increase of 8.32% [2]. - Among the top ten circulating shareholders, the China Securities White Wine Index A (161725) ranks as the sixth largest, holding 20.9613 million shares, an increase of 6.4165 million shares compared to the previous period [3]. Market Activity - On October 22, Jinhuijiu's stock price was reported at 19.87 yuan per share, with a trading volume of 62.0491 million yuan and a turnover rate of 0.61%, resulting in a total market capitalization of 10.079 billion yuan [1]. - The net outflow of main funds was 6.2274 million yuan, with large orders buying 4.2784 million yuan (6.90% of total) and selling 10.5058 million yuan (16.93% of total) [1].

10月22日，中国海油盘中上涨2.02%，截至11:29，报26.74元/股，成交10.72亿元，换手率1.35%，总市 值12709.51亿元。 资料显示，中国海洋石油有限公司位于北京市东城区朝阳门北大街25号,香港花园道1号中银大厦65层， 成立日期1999年8月20日，上市日期2022年4月21日，公司主营业务涉及中国海洋石油有限公司是一家主 要从事原油和天然气的勘探、生产及销售的中国公司。该公司经营三个分部。勘探及生产分部从事常规 油气业务、页己油气业务、油砂业务和其他非常规油气业务。贸易业务分部从事原油转口贸易业务。公 司业务分部从事总部管理、资金管理以及研究开发等业务。该公司主要在中国、加拿大、美国、英国、 尼日利亚以及巴西等地开展业务。主营业务收入构成为：油气销售82.73%，贸易14.96%，其他(补 充)2.31%。 中国海油所属申万行业为：石油石化-油气开采Ⅱ-油气开采Ⅲ。所属概念板块包括：融资融券、高派 息、增持回购、油气勘探、风能等。 截至6月30日，中国海油股东户数23.28万，较上期减少0.25%；人均流通股12936股，较上期增加 5.50%。2025年1月-6月，中国海油实现营 ...

Core Points - The stock price of Fala Electronics dropped by 2.02% on October 22, reaching 120.10 CNY per share with a trading volume of 145 million CNY and a turnover rate of 0.53% [1] - The company has a total market capitalization of 27.023 billion CNY and has seen a year-to-date stock price increase of 2.72% [1] - Fala Electronics specializes in the research, production, and sales of film capacitors, with 94.28% of its revenue coming from capacitors [1] Financial Performance - For the first half of 2025, Fala Electronics reported a revenue of 2.499 billion CNY, representing an 18.05% year-on-year growth, and a net profit attributable to shareholders of 569 million CNY, up 18.15% year-on-year [2] - The company has distributed a total of 4.38 billion CNY in dividends since its A-share listing, with 1.305 billion CNY distributed in the last three years [2] Shareholder Structure - As of June 30, 2025, the number of shareholders for Fala Electronics was 17,700, a decrease of 11.03% from the previous period [2] - The largest shareholder, Hong Kong Central Clearing Limited, holds 15.8777 million shares, a decrease of 2.386 million shares from the previous period [2]

Core Viewpoint - Zhendemedical has shown significant stock price appreciation in 2023, with a year-to-date increase of 239.03% and notable recent trading activity, indicating strong investor interest and market performance [2][3]. Stock Performance - As of October 22, Zhendemedical's stock price reached 72.35 CNY per share, with a trading volume of 4.75 billion CNY and a market capitalization of 19.278 billion CNY [1]. - The stock has experienced a 239.03% increase year-to-date, an 11.57% increase over the last five trading days, and an 85.51% increase over the last 20 days [2]. Trading Activity - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) three times this year, with the latest instance on October 13, where it recorded a net buy of 41.3766 million CNY [2]. - The total buying amount on that day was 225 million CNY, accounting for 23.61% of total trading volume, while total selling was 184 million CNY, making up 19.28% [2]. Company Overview - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, is located in Shaoxing, Zhejiang Province, and specializes in the production, research, and sales of medical dressings [2]. - The company's revenue composition includes: 43.04% from surgical infection control, 20.46% from basic care, 18.59% from ostomy and modern wound care, 10.75% from pressure treatment and fixation, 6.58% from infection control protection, and 0.58% from other sources [2]. Financial Performance - For the first half of 2025, Zhendemedical reported a revenue of 2.1 billion CNY, reflecting a year-on-year growth of 2.83%, while the net profit attributable to shareholders was 128 million CNY, down 20.70% year-on-year [3]. - The company has distributed a total of 1.46 billion CNY in dividends since its A-share listing, with 706 million CNY distributed over the past three years [4]. Shareholder Information - As of June 30, 2025, the number of shareholders was 22,600, a decrease of 8.29% from the previous period, with an average of 11,767 shares held per shareholder, an increase of 9.04% [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.7482 million shares, an increase of 80,700 shares from the previous period, while the招商核心竞争力混合A fund holds 3.4286 million shares, an increase of 581,000 shares [4].

Core Points - Jianmin Group's stock price increased by 2.06% on October 21, reaching 40.58 CNY per share, with a total market capitalization of 6.225 billion CNY [1] - The company has experienced a 0.49% decline in stock price year-to-date, with a 2.14% increase over the last five trading days [2] - Jianmin Group's main business involves the research, manufacturing, wholesale, and retail of pharmaceuticals, with 99.47% of revenue coming from product sales [2] Financial Performance - For the first half of 2025, Jianmin Group reported operating revenue of 1.805 billion CNY, a year-on-year decrease of 10.20%, and a net profit attributable to shareholders of 221 million CNY, down 7.83% year-on-year [2] - The company has distributed a total of 1.114 billion CNY in dividends since its A-share listing, with 476 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.30% to 17,000, while the average circulating shares per person decreased by 22.66% to 9,011 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 203.04 million shares, and new entrant Rongtong Health Industry Flexible Allocation Mixed A/B [3]

Core Viewpoint - Haoyang Co., Ltd. has experienced fluctuations in stock performance, with a recent increase in share price and notable changes in shareholder structure and financial performance [1][2][3]. Financial Performance - As of June 30, 2025, Haoyang Co., Ltd. reported a revenue of 522 million yuan, a year-on-year decrease of 21.99% [2]. - The net profit attributable to shareholders was 77.75 million yuan, down 61.69% compared to the previous year [2]. - The company has distributed a total of 654 million yuan in dividends since its A-share listing, with 552 million yuan distributed over the past three years [3]. Stock Performance - On October 21, 2023, Haoyang's stock price rose by 2.03%, reaching 41.19 yuan per share, with a trading volume of 26.27 million yuan and a turnover rate of 0.80% [1]. - Year-to-date, the stock has decreased by 3.87%, but it has increased by 9.11% over the last five trading days [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 9.03% to 10,700, while the average number of tradable shares per shareholder decreased by 8.29% to 7,620 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 3.54 million shares, a decrease of 40.47% from the previous period [3].

Core Insights - Glacier Network's stock price increased by 2.04% on October 21, reaching 39.06 CNY per share, with a total market capitalization of 9.158 billion CNY [1] - The company has seen a year-to-date stock price increase of 97.67%, with a recent 5-day increase of 2.52% and a 20-day decrease of 5.90% [1] Financial Performance - For the first half of 2025, Glacier Network reported a revenue of 1.257 billion CNY, representing a year-on-year growth of 4.21%, and a net profit attributable to shareholders of 336 million CNY, which is a significant increase of 165.19% [2] - The company has distributed a total of 841 million CNY in dividends since its A-share listing, with 583 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 140.76% to 44,200, while the average number of tradable shares per shareholder decreased by 58.42% to 3,735 shares [2] - Major shareholders include Hong Kong Central Clearing Limited and Huaxia CSI Animation Game ETF, with significant increases in their holdings [3]

Core Insights - Longqi Technology's stock price increased by 2.10% to 44.72 CNY per share, with a market capitalization of 20.991 billion CNY as of October 21 [1] - The company has seen a year-to-date stock price decline of 3.32%, with a recent 60-day increase of 12.84% [1] - Longqi Technology's main business revenue composition includes 70.44% from smartphones, 16.68% from AIoT products, and 9.55% from tablets [1] Financial Performance - For the first half of 2025, Longqi Technology reported a revenue of 19.908 billion CNY, a year-on-year decrease of 10.65%, while net profit attributable to shareholders was 356 million CNY, reflecting a year-on-year growth of 5.01% [2] - Cumulative cash dividends paid by Longqi Technology since its A-share listing amount to 461 million CNY [3] Shareholder Information - As of June 30, Longqi Technology had 23,400 shareholders, an increase of 22.55% from the previous period, with an average of 11,388 circulating shares per shareholder, a decrease of 18.40% [2]

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a 43.27% increase, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the early stages of new drug development, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, up 41.60% year-on-year [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which is the second-largest shareholder with 4.2526 million shares, and Agricultural Bank of China Medical Health Stock, which increased its holdings by 17.75% [2].